AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Jade Biosciences, Inc. Director's Dealing 2021

Jun 30, 2021

33383_dirs_2021-06-29_a751d632-d26c-40ba-bc86-4a295b52f95d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aerovate Therapeutics, Inc. (AVTE)
CIK: 0001798749
Period of Report: 2021-06-29

Reporting Person: Iwicki Mark T (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$2.144	2031-04-01	Common Stock (39550)		Direct
Stock Option (Right to Buy)	$2.144	2031-04-01	Common Stock (76747)		Direct

Footnotes

F1: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vested on March 12, 2021.

F2: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on July 4, 2021.